Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data

Yuanyuan Gu, Sonia García-Pérez, John Massie, Kees van Gool

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Cystic fibrosis (CF) is a progressive disease with treatments intensifying as patients get older and severity worsens. To inform policy makers about the cost burden in CF, it is crucial to understand what factors influence the costs and how they affect the costs. Based on 1,060 observations (from 731 patients) obtained from the Australian Data Registry, individual annual health care costs were calculated and a regression analysis was carried out to examine the impact of multiple variables on the costs. A method of retransformation and a hypothetical patient were used for cost analysis. We show that an additional one unit improvement of FEV1pp (i.e., forced expiratory volume in 1 s as a percentage of predicted volume) reduces the costs by 1.4 %, or for a hypothetical patient whose FEV1pp is 73 the cost reduction is A$252. The presence of chronic infections increases the costs by 69.9–163.5 % (A$12,852–A$30,047 for the hypothetical patient) depending on the type of infection. The type of CF genetic mutation and the patient’s age both have significant effects on the costs. In particular, being homozygous for p.F508del increases the costs by 26.8 % compared to all the other gene mutations. We conclude that bacterial infections have a very strong influence on the costs, so reducing both the infection rates and the severity of the condition may lead to substantial cost savings. We also suggest that the patient’s genetic profile should be considered as an important cost determinant.

LanguageEnglish
Pages709-717
Number of pages9
JournalEuropean Journal of Health Economics
Volume16
Issue number7
DOIs
Publication statusPublished - 14 Sep 2015
Externally publishedYes

Fingerprint

Cystic Fibrosis
Registries
Costs and Cost Analysis
Registry
Cystic fibrosis
Costs
Infection
Mutation
Cost Savings
Forced Expiratory Volume
Administrative Personnel
Bacterial Infections
Health Care Costs
Regression Analysis

Cite this

Gu, Yuanyuan ; García-Pérez, Sonia ; Massie, John ; van Gool, Kees. / Cost of care for cystic fibrosis : an investigation of cost determinants using national registry data. In: European Journal of Health Economics. 2015 ; Vol. 16, No. 7. pp. 709-717.
@article{3795f18343274d0c91ec311c75707746,
title = "Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data",
abstract = "Cystic fibrosis (CF) is a progressive disease with treatments intensifying as patients get older and severity worsens. To inform policy makers about the cost burden in CF, it is crucial to understand what factors influence the costs and how they affect the costs. Based on 1,060 observations (from 731 patients) obtained from the Australian Data Registry, individual annual health care costs were calculated and a regression analysis was carried out to examine the impact of multiple variables on the costs. A method of retransformation and a hypothetical patient were used for cost analysis. We show that an additional one unit improvement of FEV1pp (i.e., forced expiratory volume in 1 s as a percentage of predicted volume) reduces the costs by 1.4 {\%}, or for a hypothetical patient whose FEV1pp is 73 the cost reduction is A$252. The presence of chronic infections increases the costs by 69.9–163.5 {\%} (A$12,852–A$30,047 for the hypothetical patient) depending on the type of infection. The type of CF genetic mutation and the patient’s age both have significant effects on the costs. In particular, being homozygous for p.F508del increases the costs by 26.8 {\%} compared to all the other gene mutations. We conclude that bacterial infections have a very strong influence on the costs, so reducing both the infection rates and the severity of the condition may lead to substantial cost savings. We also suggest that the patient’s genetic profile should be considered as an important cost determinant.",
author = "Yuanyuan Gu and Sonia Garc{\'i}a-P{\'e}rez and John Massie and {van Gool}, Kees",
year = "2015",
month = "9",
day = "14",
doi = "10.1007/s10198-014-0621-5",
language = "English",
volume = "16",
pages = "709--717",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer, Springer Nature",
number = "7",

}

Cost of care for cystic fibrosis : an investigation of cost determinants using national registry data. / Gu, Yuanyuan; García-Pérez, Sonia; Massie, John; van Gool, Kees.

In: European Journal of Health Economics, Vol. 16, No. 7, 14.09.2015, p. 709-717.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost of care for cystic fibrosis

T2 - European Journal of Health Economics

AU - Gu, Yuanyuan

AU - García-Pérez, Sonia

AU - Massie, John

AU - van Gool, Kees

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Cystic fibrosis (CF) is a progressive disease with treatments intensifying as patients get older and severity worsens. To inform policy makers about the cost burden in CF, it is crucial to understand what factors influence the costs and how they affect the costs. Based on 1,060 observations (from 731 patients) obtained from the Australian Data Registry, individual annual health care costs were calculated and a regression analysis was carried out to examine the impact of multiple variables on the costs. A method of retransformation and a hypothetical patient were used for cost analysis. We show that an additional one unit improvement of FEV1pp (i.e., forced expiratory volume in 1 s as a percentage of predicted volume) reduces the costs by 1.4 %, or for a hypothetical patient whose FEV1pp is 73 the cost reduction is A$252. The presence of chronic infections increases the costs by 69.9–163.5 % (A$12,852–A$30,047 for the hypothetical patient) depending on the type of infection. The type of CF genetic mutation and the patient’s age both have significant effects on the costs. In particular, being homozygous for p.F508del increases the costs by 26.8 % compared to all the other gene mutations. We conclude that bacterial infections have a very strong influence on the costs, so reducing both the infection rates and the severity of the condition may lead to substantial cost savings. We also suggest that the patient’s genetic profile should be considered as an important cost determinant.

AB - Cystic fibrosis (CF) is a progressive disease with treatments intensifying as patients get older and severity worsens. To inform policy makers about the cost burden in CF, it is crucial to understand what factors influence the costs and how they affect the costs. Based on 1,060 observations (from 731 patients) obtained from the Australian Data Registry, individual annual health care costs were calculated and a regression analysis was carried out to examine the impact of multiple variables on the costs. A method of retransformation and a hypothetical patient were used for cost analysis. We show that an additional one unit improvement of FEV1pp (i.e., forced expiratory volume in 1 s as a percentage of predicted volume) reduces the costs by 1.4 %, or for a hypothetical patient whose FEV1pp is 73 the cost reduction is A$252. The presence of chronic infections increases the costs by 69.9–163.5 % (A$12,852–A$30,047 for the hypothetical patient) depending on the type of infection. The type of CF genetic mutation and the patient’s age both have significant effects on the costs. In particular, being homozygous for p.F508del increases the costs by 26.8 % compared to all the other gene mutations. We conclude that bacterial infections have a very strong influence on the costs, so reducing both the infection rates and the severity of the condition may lead to substantial cost savings. We also suggest that the patient’s genetic profile should be considered as an important cost determinant.

UR - http://www.scopus.com/inward/record.url?scp=84938963191&partnerID=8YFLogxK

U2 - 10.1007/s10198-014-0621-5

DO - 10.1007/s10198-014-0621-5

M3 - Article

VL - 16

SP - 709

EP - 717

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - 7

ER -